Accordo di distribuzione di ColdZyme per Iraq e Giordania
La svedese Enzymatica AB ha siglato una partnership con MedonyX per la distribuzione esclusiva del suo spray orale ColdZyme in Iraq e Giordania. Questo accordo a lungo termine mira ad espandere la presenza del prodotto sul mercato nei settori sanitari chiave del Medio Oriente.
Enzymatica AB has successfully secured a long-term exclusive distribution agreement with MedonyX to bring its flagship ColdZyme mouth spray to Iraq and Jordan. MedonyX is backed by MMDS, a prominent Jordanian healthcare and market-access firm with deep regional expertise. The partnership covers the comprehensive registration, marketing, sales, and distribution processes necessary for a successful regional rollout. Both companies anticipate a strong market entry as consumer demand for preventative healthcare solutions remains robust in the Middle East. This strategic expansion represents a milestone for Enzymatica as it seeks to scale its international footprint beyond traditional European markets. Financial terms of the agreement were not disclosed, but initial product launches are already slated for both territories.
Avviso sull'analisi IA
L'analisi dell'impatto sugli asset è generata dall'IA e ha solo scopo informativo. Non costituisce consulenza finanziaria. Fai sempre le tue ricerche prima di prendere decisioni di investimento.
Discussione